2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments

12 September 2017

Biosimilar medicines are transforming treatment by enabling better access to […]

Oncology, the new era for biosimilar medicines

8 September 2017

With more than 10 years of positive experience and 700 […]

Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation

5 September 2017

A new study “Value Added Medicines: Time to Adjust the […]

País pode poupar “mais 100 milhões por ano” com genéricos

18 July 2017

Europäer zahlen zu viel für Pillen

18 July 2017

“É possível fazer os médicos portugueses prescreverem mais genéricos”

18 July 2017

Jacek Glinka: “Biossimilares podem poupar ao SNS 120 milhões de euros”

18 July 2017

Pharma expert: EU drug agency should be ‘easily’ accessible to all

18 July 2017

Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health

16 June 2017

Biosimilar medicines are transforming treatment by enabling better access to […]

62% of Medicines Dispensed in Europe are Generic, according to IMS New Data

15 June 2017

Pharmaceutical industry leaders and key stakeholders from the generic, biosimilar […]